Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044278 · ClinicalTrials.gov registry record · Phase 2
Pediatric Epilepsy Study in Subjects 1-24 Months
A Phase 2 study of Epilepsy, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 197
- Enrollment target
- 20
- Study locations
NCT00044278: Completed Phase 2 study of Epilepsy, sponsored by GlaxoSmithKline.
NCT00044278 is a Phase 2 study of Epilepsy that has completed, run by GlaxoSmithKline. The registered enrollment target is 197 participants, below the 951-participant average among 160 other Epilepsy trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00044278, a Phase 2 study of Epilepsy, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 197 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the long-term safety of LAMICTAL(lamotrigine)in subjects with partial seizures previously enrolled in protocol LAM20006 and in subjects 1-24 months of age who have never received LAMICTAL(LAMICTAL-naive). For LAMICTAL-naive subjects, LAMICTAL will be added to the subject's current epilepsy medications.
Conditions Studied
Interventions
- DRUG lamotrigine
Study Locations (20)
Florida
- GSK Investigational Site - Jacksonville
- GSK Investigational Site - Miami
- GSK Investigational Site - Orlando
- GSK Investigational Site - Tallahassee
- GSK Investigational Site - Tampa
California
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Stanford
Arkansas
- GSK Investigational Site - Jonesboro
- GSK Investigational Site - Little Rock
Georgia
- GSK Investigational Site - Atlanta
- GSK Investigational Site - Augusta
Missouri
- GSK Investigational Site - Columbia
- GSK Investigational Site - Kansas City
Alabama
- GSK Investigational Site - Mobile
Arizona
- GSK Investigational Site - Tucson
Colorado
- GSK Investigational Site - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2000-09 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
What the finished NCT00044278 record still lists
NCT00044278 is an interventional study that assigns participants to a tested intervention. The registered 197 participants enrollment target is mid-sized for trials with a published cap, below the 951-participant average among 160 other Epilepsy trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which lamotrigine is the first listed.
NCT00044278 names 20 study sites across 11 states, led by Florida, California, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00044278 about?
NCT00044278 is a clinical study titled "Pediatric Epilepsy Study in Subjects 1-24 Months". This study will evaluate the long-term safety of LAMICTAL(lamotrigine)in subjects with partial seizures previously enrolled in protocol LAM20006 and in subjects 1-24 months of age who have never received LAMICTAL(LAMICTAL-naive). For LAMICTAL-naive subjects, LAMICTAL will be added to the subject's c...
What is the current status of trial NCT00044278?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 197 participants. The study started on 2000-09. Estimated completion is 2006-06.
What conditions does trial NCT00044278 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT00044278?
The interventions under investigation include: lamotrigine (DRUG).
Who is sponsoring clinical trial NCT00044278?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00044278 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00044278's enrollment target sits among peer trials
197 33rd of 160 higher than 128 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
RECRUITING · Phase 2
-
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
RECRUITING · Phase 2
-
RNS System LGS Feasibility Study
ACTIVE NOT RECRUITING · Phase 2
-
Study of an External Responsive Neurostimulator System on Epileptiform Activity
COMPLETED · Phase 2
-
Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI
COMPLETED · Phase 2
-
Hormone Replacement in Menopausal Women With Epilepsy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04219254 · 197 participants · Phase 1
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
- NCT06173778 · 197 participants · Phase 2
Semaglutide for Post-Smoking Cessation Weight Management
- NCT05203328 · 198 participants · NA
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
- NCT05426967 · 198 participants · NA
rTMS for Military TBI-related Depression
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia